Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies.
作者： Derry C. Roopenian , Gregory J. Christianson , Thomas J. Sproule
DOI: 10.1007/978-1-60761-058-8_6
关键词:
摘要: Therapeutic monoclonal antibodies are widely recognized to be a most promising means treat an increasing number of human diseases, including cancers and autoimmunity. To large extent, the efficacy antibody treatment is because IgG have greatly extended persistence in vivo. However, conventional rodent models do not mirror pharmacokinetics. The key molecule responsible for major histocompatibility complex class I family Fc receptor, FcRn. We describe FcRn transgenic mouse how they can exploited productively preclinical pharmacokinetic evaluation therapeutic antibodies.
springer.com
sci-hub.st 参考文章(21)
F. M. Burnet, Frank Fenner, The production of antibodies ,(1949)
Neil E. Simister, Debra J. Gilbert, Nancy A. Jenkins, Jeremy J. Ahouse, Neal G. Copeland, Chanah L. Hagerman, Plavi Mittal, Mouse MHC class I-like Fc receptor encoded outside the MHC. Journal of Immunology. ,vol. 151, pp. 6076- 6088 ,(1993)
Derry C. Roopenian, Gregory J. Christianson, Thomas J. Sproule, Aaron C. Brown, Shreeram Akilesh, Nadja Jung, Stefka Petkova, Lia Avanessian, Eun Young Choi, Daniel J. Shaffer, Peter A. Eden, Clark L. Anderson, The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs Journal of Immunology. ,vol. 170, pp. 3528- 3533 ,(2003) , 10.4049/JIMMUNOL.170.7.3528
P. Deckert, Current constructs and targets in clinical development for antibody-based cancer therapy. Current Drug Targets. ,vol. 10, pp. 158- 175 ,(2009) , 10.2174/138945009787354502
Raimund J. Ober, Caius G. Radu, Victor Ghetie, E. Sally Ward, Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies International Immunology. ,vol. 13, pp. 1551- 1559 ,(2001) , 10.1093/INTIMM/13.12.1551
Blair Jarvis, Diana Faulds, Etanercept: a review of its use in rheumatoid arthritis. Drugs. ,vol. 57, pp. 945- 966 ,(1999) , 10.2165/00003495-199957060-00014
Jonathan Zalevsky, Aaron K Chamberlain, Holly M Horton, Sher Karki, Irene W L Leung, Thomas J Sproule, Greg A Lazar, Derry C Roopenian, John R Desjarlais, Enhanced antibody half-life improves in vivo activity Nature Biotechnology. ,vol. 28, pp. 157- 159 ,(2010) , 10.1038/NBT.1601
Xiao-yun Liu, Laurentiu M. Pop, Ellen S. Vitetta, Engineering therapeutic monoclonal antibodies Immunological Reviews. ,vol. 222, pp. 9- 27 ,(2008) , 10.1111/J.1600-065X.2008.00601.X
Neil E. Simister, Keith E. Mostov, An Fc receptor structurally related to MHC class I antigens. Nature. ,vol. 337, pp. 184- 187 ,(1989) , 10.1038/337184A0
Wilhelm P. Burmeister, Andrew H. Huber, Pamela J. Bjorkman, Crystal structure of the complex of rat neonatal Fc receptor with Fc Nature. ,vol. 372, pp. 379- 383 ,(1994) , 10.1038/372379A0